Halting the Epidemic of Addiction and Loss Act of 2025
Sponsored By: Senator John Cornyn
Introduced
Summary
Makes HHS grant rules explicitly cover any FDA-approved opioid overdose reversal drug. It would require the HHS Secretary to update existing regulations and guidance within one year after enactment so any reference to an "opioid overdose reversal drug" in the State and Tribal Opioid Response grants (section 1003 of the 21st Century Cures Act) and the priority prevention grants (section 516 of the Public Health Service Act) includes any drug approved or authorized by the Food and Drug Administration under section 505 for emergency treatment of a known or suspected opioid overdose.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Broader language for overdose drugs
This bill would require HHS to make its rules and guidance cover any opioid overdose reversal drug the FDA approves or authorizes. An example is naloxone. If enacted, HHS would have to update rules or guidance issued before enactment within one year after enactment. The updates would include State and Tribal Opioid Response Grants and the Public Health Service Act section 516 grant program. HHS would also use the same inclusive language in future grant rules and guidance.
Sponsors & CoSponsors
Sponsor
John Cornyn
TX • R
Cosponsors
Maggie Hassan
NH • D
Sponsored 7/17/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in